• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Aggrenox (aspirin/extended-release dipyridamole capsules)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Aggrenox (aspirin/extended-release dipyridamole capsules)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Stroke occurs when blood clots block blood flow to the brain. Aggrenox acts as an antiplatelet, preventing blood platelets from aggregating to form the dangerous clots.

    Platelet aggregation is actually a natural process which allows platelet cells to stick together and adhere to the blood vessel wall to prevent excessive blood loss when a blood vessel is damaged. However, for patients who have high-risk of blood clotting, this mechanism can be dangerous. Aggrenox works to prevent the clotting in patients, such as stroke victims, who fall into this high-risk category.

    Stroke, the third leading cause of death in the United States, afflicts 730,000 Americans in all and kills approximately 160,000 of those victims each year. Recurrance rate over five years ranges from 30% to nearly 50%, so a drug like Aggrenox which lowers the risk for recurrance is essential.

    Clinical Results

    Results of the European Stroke Prevention Study 2 (ESPS2), which involved over 6,600 patients, indicated that Aggrenox reduces the risk of recurrent stroke by 37% compared to placebo. Aspirin-only regimens reduced the risk by only 18% as compared to the placebo.
    In addition, the results of the study indicated that Aggrenox may reduce risk for secondary stroke more effectively than Clopidogrel, another antiplatelet, although direct- comparison studies between the two drugs have not yet been done.

    Side Effects

    Although Aggrenox generally well-tolerated, it was shown to induce headache, bleeding, and gastrointestinal events in some patients undergoing the treatment.

    Mechanism of Action

    Aggrenox is an aspirin/extended-release dipyridamole combination that acts on multiple mechanisms of the platelet-aggregation process to prevent clumping and clotting.

    Literature References

    Gregory W. Albers, Robert G. Hart, Helmi L. Lutsep, David W. Newell, and Ralph L. Sacco. "Supplement to the Guidelines for the Management of Transient Ischemic Attacks," Stroke, November 1999, Vol 30:2502-2511.

    Visit the following online sites for more information about Aggrenox, strokes, and stroke-related issues:


    • The National Stroke Association. www.stroke.org or call 1-800-STROKES
    • Stroke; the Journal of the American Heart Association. stroke.ahajournals.org
    • Boehringer Ingelheim Pharmaceuticals, Inc. www.boehringer-ingelheim.com

    Additional Information

    Recognize the Symptoms of Stroke!

    • Sudden numbness of face, arm, or leg, especially on one side of the body
    • Sudden confusion; trouble speaking or understanding
    • Sudden trouble seeing in one or both eyes
    • Sudden trouble walking, dizziness, loss of balance or coordination
    • Sudden severe headache with no known cause

    If you experience any of these symptoms, seek emergency medical attention immediately! Stroke is very serious and can "cascade" rapidly, but treatment can be more effective if given quickly.

    Approval Date: 1999-11-01
    Company Name: Boehringer Ingelheim
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing